Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Public comment period · §3

Draft standard CEI-MS-09: Assessment of appearance, cake… — disposition

The disposition of every submission and the amendments that resulted.

Document identifier
CEI-CP-095/3
Series
Public comment period
Version
1.0
Published
24 Jun 2025
Last reviewed
24 Jun 2025
Next review
24 Jun 2026
Identifier
10.71829/cei.cp.95
Certainty
Not rated
Cycle
2025 Q2
Window
08 Apr 2025 – 03 Jun 2025
Status
Closed
Submissions
13

§3Disposition and amendments

§3.1Disposition table

Table 1. Every submission with its disposition. Each row links to the submission in full.

ReferenceRespondentPoint raisedDisposition
DRAFT-APPEARANCE-S/008Hortensia Beauchamp-Ekong industryThe additional determinations required would materially increase release testing costAccepted in part
DRAFT-APPEARANCE-S/007Dr Gervase AbergavennyThe document is unreadable without specialist trainingAccepted in part
DRAFT-APPEARANCE-S/011Dr Anselm Ashworth-DanquahThe document should state what a reader ought to doNot accepted
DRAFT-APPEARANCE-S/005Dr Beatrijs HazelriggNothing requires the report to state who performed the determinationAccepted
DRAFT-APPEARANCE-S/006Dr Georgiana ZimmerthalA sortable table implies a comparison the underlying data do not supportNoted, no amendment
DRAFT-APPEARANCE-S/010Dr Hyacinth Drakeford-AmadiThe limitations section states what the method cannot do but not what a reader will wrongly concludeAccepted
DRAFT-APPEARANCE-S/013Dr Vasilisa ImmelmannTerms are used in senses that differ from established pharmacopoeial usageAccepted
DRAFT-APPEARANCE-S/012Dr Bertrand Steenkamp-FerreiraThe scope does not say which materials the standard excludesAccepted
DRAFT-APPEARANCE-S/009Professor Bartolomeu Nkosi-LindegaardThe matrix interferes with the determination and no control is requiredAccepted
DRAFT-APPEARANCE-S/003Hortensia HollingworthThe search date is not on the face of the documentAccepted
DRAFT-APPEARANCE-S/002Dr Thaddeus Isaksen-Balogun industryThe document should not describe uses outside the approved indicationNot accepted
DRAFT-APPEARANCE-S/004Dr Frideswide HazelriggPoint estimates are given without an intervalAccepted in part
DRAFT-APPEARANCE-S/001Dr Melisande Kirkpatrick-OlaNothing requires a laboratory to demonstrate ongoing performanceAccepted in part
13 submissions in total.

§3.2Summary by disposition

Table 2. Counts by disposition, with the meaning of each.

DispositionCountMeaning
Accepted6The submission is accepted and the draft is amended as proposed. The amendment is recorded in the amendment log of the document it changed and is traceable to the numbered submission.
Accepted in part4Part of the submission is accepted and part is not. The secretariat response states which part is which and on what ground the remainder was declined.
Noted, no amendment1The submission raises a point the Institute accepts but that does not require a change to the draft, most often because the draft already states it elsewhere. The location is given in the response.
Not accepted2The submission is not accepted. The secretariat response gives the reason. A submission that is not accepted remains published in full; the Institute does not remove a submission because it disagrees with it.

§3.3Resulting amendments

  1. The additional determinations required would materially increase release testing cost — arising from DRAFT-APPEARANCE-S/008. One of the two determinations is now required only where the stated risk factor is present, with the factor defined in the scope, and the other is retained as a universal requirement with the reasoning stated. The submission is identified as an industry…
  2. The document is unreadable without specialist training — arising from DRAFT-APPEARANCE-S/007. Every document now opens with a plain-language summary of not more than 150 words, placed above the technical abstract and carrying the same certainty language, so that the two cannot diverge.
  3. Nothing requires the report to state who performed the determination — arising from DRAFT-APPEARANCE-S/005. The report now requires the identity of the laboratory that performed the determination, its accreditation status where claimed, and a statement of whether the releasing party is the performing party, with the fields classified as critical.
  4. The limitations section states what the method cannot do but not what a reader will wrongly conclude — arising from DRAFT-APPEARANCE-S/010. The limitations section now lists the specific conclusions a conformant determination does not support, each stated as a sentence a reader could otherwise have written, and the list is placed before the references rather than in an annex.
  5. Terms are used in senses that differ from established pharmacopoeial usage — arising from DRAFT-APPEARANCE-S/013. The three terms now follow established pharmacopoeial usage, the glossary records the definition and its source, and where the Institute uses a term in a narrower sense the departure is stated at first use in the standard.
  6. The scope does not say which materials the standard excludes — arising from DRAFT-APPEARANCE-S/012. The scope now states both what the standard applies to and what it does not, with the excluded classes named and, where another standard covers them, cross-referenced.
  7. The matrix interferes with the determination and no control is required — arising from DRAFT-APPEARANCE-S/009. An inhibition and enhancement control is now required for every determination under this standard, with stated recovery limits, and a determination reported without it is recorded as not conformant rather than as a low result.
  8. The search date is not on the face of the document — arising from DRAFT-APPEARANCE-S/003. The search date is now printed adjacent to every certainty rating and is carried in the document metadata, so that the interval between the search and the reading is visible without reference to the methods section.
  9. Point estimates are given without an interval — arising from DRAFT-APPEARANCE-S/004. Every estimate now carries its interval where the source reported one, and where it did not, the estimate is annotated as reported without an interval rather than left to appear as a precise figure.
  10. Nothing requires a laboratory to demonstrate ongoing performance — arising from DRAFT-APPEARANCE-S/001. The standard now requires that system suitability results be trended across runs and that a determination report whether the trend was within the laboratory's stated limits, which places the demonstration inside the document the Institute can read.

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

  1. International Organization for Standardization. ISO/IEC 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories. ISO/IEC Standard 2017;3rd edition. identifier not held by the Institute

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.